BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tobevibart (VIR-3434) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tobevibart (VIR-3434)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07128550-9829@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tobevibart (VIR-3434): Phase 3 readout est. (NCT07128550)
DESCRIPTION:Tobevibart (VIR-3434)\, phase 3\, Chronic Hepatitis Delta.\nStu
 dy: A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic 
 HDV Infection Not Virologically Suppressed With Bulevirtide\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tobevibart-vir-3434#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07128550
URL:https://assetmemo.bio/drug/tobevibart-vir-3434#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07142811-9829@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Tobevibart (VIR-3434): Phase 2 readout est. (NCT07142811)
DESCRIPTION:Tobevibart (VIR-3434)\, phase 2\, Chronic Hepatitis Delta.\nStu
 dy: A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic
  HDV Infection\nEstimated primary completion: March 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tobevibart-vir-3434#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07142811
URL:https://assetmemo.bio/drug/tobevibart-vir-3434#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06216470-9829@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tobevibart (VIR-3434): Phase 2 readout est. (NCT06216470)
DESCRIPTION:Tobevibart (VIR-3434)\, phase 2.\nStudy: Vaccinal Effect of HBs
 Ag Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]\nEstim
 ated primary completion: December 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tobevibart-vir-3434#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06216470
URL:https://assetmemo.bio/drug/tobevibart-vir-3434#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05461170-9829@assetmemo.bio
DTSTAMP:20261121T005020Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Tobevibart (VIR-3434): Phase 2 readout est. (NCT05461170)
DESCRIPTION:Tobevibart (VIR-3434)\, phase 2.\nStudy: SOLSTICE: Combination 
 Therapy for the Treatment of Chronic Hepatitis D Infection.\nEstimated pri
 mary completion: November 2031. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tobevibart-vir-3434#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05461170
URL:https://assetmemo.bio/drug/tobevibart-vir-3434#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
